SCHEMBL10243039

SCHEMBL10243039

CCNC(=O)OCc1cccc(N)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
HTT P42858 1/20 0.42
MAPT P10636 1/20 0.42
THRA P10827 1/20 0.41
THRB P10828 1/20 0.41
MGLL Q99685 1/20 0.40
PRSS1 P07477 1/20 0.40
TPSAB1 Q15661 1/20 0.40
TPSD1 Q9BZJ3 1/20 0.40
TPSG1 Q9NRR2 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
TACR1 P25103 1/20 0.40
PLAU P00749 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Aniline SCHEMBL27715502 0.86 LMNA (0.56) LMNASMN1; SMN2L3MBTL1HTTMAPT
SCHEMBL6206459 0.84 TOP2A (0.52) LMNASMN1; SMN2THRATHRBMGLL
SCHEMBL14233717 0.83 LMNA (0.45) LMNASMN1; SMN2L3MBTL1HTTMAPT
SCHEMBL14233691 0.82 SMN1; SMN2 (0.42) LMNASMN1; SMN2L3MBTL1HTTMAPT
SCHEMBL25852781 0.82 HCAR2 (0.54) L3MBTL1HTT
SCHEMBL10242970 0.82 GLA (0.54)
Hydrochloric Acid SCHEMBL7212599 0.81 L3MBTL1 (0.46) LMNASMN1; SMN2L3MBTL1HTTMAPT
SCHEMBL22198338 0.81 TPSAB1 (0.48) LMNASMN1; SMN2L3MBTL1HTTMAPT
SCHEMBL3865410 0.81 PLAU (0.58) LMNASMN1; SMN2L3MBTL1HTTMGLL
SCHEMBL4439076 0.81 TACR1 (0.48) SMN1; SMN2THRATHRBMGLLNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 LMNA 1467/4885SMN1; SMN2 3120/4885L3MBTL1 2853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.